B-cell NHL Biomarker Mutation Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and classifying B-cell Non-Hodgkin Lymphomas (NHLs), particularly follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), are challenging due to limited understanding of genetic events and heterogeneity, leading to disparities in response to therapy.
Innovation Solution
Identification of somatic mutations and biomarkers such as MLL2, MEF2B, CREBBP, EP300, EZH2, and HDAC7, which are involved in histone modification, to develop methods for testing samples for these mutations, enabling improved identification and classification of B-cell NHLs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods for identifying B-cell NHLs are used, then the diagnostic process is simple, but the identification precision and classification accuracy are insufficient
Solution Approach 1:
The patent segments the complex diagnostic process into distinct stages: initial screening for specific genetic abnormalities (t(14;18), c-REL amplification, PRDM1 alterations), followed by subtype classification based on additional markers. This segmentation allows for systematic identification of B-cell NHL subtypes while managing complexity through a structured approach to genetic analysis
Solution Approach 2:
The patent changes the diagnostic parameters from conventional morphology-based classification to genetics-based classification. By detecting specific genetic abnormalities and mutation profiles (such as EZH2 Y641 mutations, NF-κB pathway alterations), the method achieves higher identification precision while providing objective, quantifiable diagnostic criteria
2Measurement precision
If genetic testing for multiple biomarkers is performed, then the classification accuracy improves, but the testing complexity and cost increase
Solution Approach 1:
The patent applies preliminary action by first testing for common, high-yield genetic abnormalities (t(14;18) translocation, c-REL amplification) before proceeding to more complex subtype classification. This staged approach allows clinicians to identify cases with high probability of specific subtypes using simpler tests first, reserving more complex multi-marker analysis for cases requiring precise subtype differentiation
Solution Approach 2:
The patent develops a universal diagnostic framework that can identify multiple B-cell NHL subtypes (GCB-DLBCL, ABC-DLBCL, FL) using a common set of genetic markers and testing methodologies. This multi-functional approach allows a single testing protocol to serve multiple diagnostic purposes, improving classification accuracy without proportionally increasing testing complexity
3Adaptability or versatility
If comprehensive genetic profiling is used, then the therapeutic selection improves, but the time required for diagnosis increases
Solution Approach 1:
The patent segments the genetic profiling process into priority tiers: first-tier markers (t(14;18), EZH2 Y641 mutations) that provide rapid subtype identification for immediate therapeutic decision-making, and second-tier markers (additional NF-κB pathway genes, microRNA profiles) that refine therapeutic selection when first-tier markers are inconclusive. This segmentation reduces initial diagnosis time while preserving comprehensive therapeutic guidance
Data Source
AI summary
The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.